Get started
Author

Brian G. M. Durie

Observed names: B DURIE, B Durie, B G Durie, B G M Durie, B. Durie, B. G. M. Durie, B.G. Durie, B.G.M Durie, B.G.M. Durie, Brian G.M Durie, Brian G.M. Durie, Brian GM. Durie, Brian M. Durie
OpenAlex ID: A5111546433
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
1989 · W S Dalton, T M Grogan, et al. · Journal of Clinical Oncology · 556
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
2017 · S K Kumar, M A Dimopoulos, et al. · Leukemia · 351
Modulation of multidrug-resistant multiple myeloma by cyclosporin
1992 · P Sonneveld, B Lowenberg, et al. · The Lancet · 315
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
2013 · E M Ocio, P G Richardson, et al. · Leukemia · 233
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
2009 · S Giralt, E A Stadtmauer, et al. · Leukemia · 231
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
1986 · B G Durie, D O Dixon, et al. · Journal of Clinical Oncology · 88
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
2008 · M A Hussein, F D Vrionis, et al. · Leukemia · 75
Doxorubicin/b.c.n.u. Chemotherapy for Multiple Myeloma in Relapse
1976 · D.S. Alberts, B.G.M. Durie, et al. · The Lancet · 54
Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas
1988 · L. Danel, C. Vincent, et al. · Journal of Steroid Biochemistry · 53
Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
1985 · B R Greenberg, B G Durie, et al. · PubMed · 52
Analysis of multidrug‐resistance (MDR‐1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma
1993 · P. Sonneveld, B. G. M. Durie, et al. · British Journal of Haematology · 46
Low-dose thalidomide in myeloma: Efficacy and biologic significance
2002 · B DURIE · Seminars in Oncology · 38
The epidemiology of multiple myeloma
2001 · Brian G.M Durie · Seminars in Hematology · 32
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
2017 · P. Musto, K.C. Anderson, et al. · Annals of Oncology · 24
Cellular Kinetics, Staging, and Immunoglobulin Synthesis in Multiple Myeloma
1975 · B G M Durie, S E Salmon · Annual Review of Medicine · 19
Acute Promyelocytic Leukemia
2007 · E C Kingsley, B G Durie, et al. · Current topics in microbiology and immunology · 14
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
2024 · Rahul Banerjee, Rachael Sexton, et al. · Blood · 12
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
2023 · Sridurga Mithraprabhu, John Reynolds, et al. · Blood Cancer Journal · 10
PDF
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis
2025 · Hira Mian, Thomas G. Martin, et al. · Leukemia · 7
Therapeutic strategies in multiple myeloma.
1980 · B G Durie, S Salmon · PubMed · 5
Failure of indium 111-labeled bleomycin tumor scanning to predict response to bleomycin (NSC-125066) treatment.
1974 · S E Jones, S E Salmon, et al. · PubMed · 5
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
2026 · Shaji Kumar, Sundar Jagannath, et al. · Blood Cancer Journal · 4
PDF
Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
2024 · Hira Mian, Carlyn Rose Tan, et al. · Blood · 3
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin
2007 · B G M Durie, S V Rajkumar · Leukemia · 3
Ps1349 Updated Risk Stratification Model for Smoldering Multiple Myeloma (smm) Incorporating the Revised Imwg Diagnostic Criteria
2019 · M.-V. Mateos, S. Kumar, et al. · HemaSphere · 1
Works count: 38
Citation count: 2,233
H-index: 15
I10-index: 18
Year
Topic
Type